Skip to main content
Figure 4 | BMC Genomics

Figure 4

From: Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues

Figure 4

JNImeta Population: Progression free survival (PFS) analyses for JNImeta ER+ advanced BC tamoxifen only treated patients by qRT-PCR grading: PCR-GGI low = blue and PCR-GGI high = red. The low-risk patients recurring 7.5 months later compared to high-risk patients (difference observed at 50% survival). Difference in progression-free survival between two groups is summarized by the hazard ratio (HR) for recurrence with its 95% CI. All statistical tests were two-sided.

Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us